6
Participants
Start Date
November 14, 2017
Primary Completion Date
December 22, 2017
Study Completion Date
December 22, 2017
[14C]-GSK2269557 IV infusion
The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
GSK2269557 via DPI
GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
[14C]-GSK2269557 oral solution
The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
GSK Investigational Site, London
Lead Sponsor
GlaxoSmithKline
INDUSTRY